Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesOmnicell Inc

Omnicell Inc

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
35.57 USD -0.33 ( 0.92%)
Last update at 2026-11-11T21:00:00Z
VOLUME
332995
Market Cap
1488.41M
P/E
38.85

Momentum Score

…

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
35.29
Low
36.18
High
52 Week Price Range
29.06
Low
55.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Omnicell provides medication-management solutions to hospitals and pharmacies, including automation hardware, software and services for dispensing, inventory and adherence. Growth may be supported by demand for automation, aging populations, pressure to reduce medication errors and cost control; its installed base and recurring service revenues could appeal to investors.

Key risks include budget-sensitive procurement and long sales cycles, strong competition from other device and software vendors, integration and execution challenges, plus regulatory, reimbursement and cybersecurity pressures that could hurt adoption and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
35.90
Dividend Yield
-
Revenue TTM
1246.70M
Revenue Per Share
27.49
Gross Profit TTM
548.73M
Debt / Equity
0.17
ROE
3.06%
Net Debt
7.83M
ROCE
1.02%
Diluted EPS TTM
0.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 11.32M 25.59M -20.11M -2.45M 66.01M
Net income 2.05M 12.53M -20.37M 5.65M 77.85M
Selling general administrative 409.61M 380.25M 464.34M 486.34M 389.43M
Gross profit 508.04M 471.00M 496.84M 588.99M 554.65M
Reconciled depreciation 86.63M 89.75M 96.45M 99.17M 84.93M
Ebit 15.23M 30.12M -34.87M -2.32M 89.51M
Ebitda 101.87M 119.87M -34.87M 96.85M 174.44M
Depreciation and amortization 86.63M 89.75M 95.56M 99.17M 84.93M
Non operating income net other - - - -0.13M -23.50M
Operating income 11.66M 0.34M -34.87M -2.32M 89.51M
Other operating expenses 1173.18M 1111.90M 1181.98M 1298.27M 1042.51M
Interest expense 3.91M 4.53M 14.76M 0.13M -23.50M
Tax provision 9.27M 13.06M -2.70M -8.10M -11.84M
Net interest income 6.17M 25.26M 12.76M -0.13M -23.50M
Income tax expense 9.27M 13.06M 0.26M -8.10M -11.84M
Total revenue 1184.85M 1112.24M 1147.11M 1295.95M 1132.02M
Total operating expenses 496.38M 470.67M 531.71M 591.31M 465.15M
Cost of revenue 676.80M 641.24M 650.27M 706.96M 577.37M
Total other income expense net -0.34M 25.26M 14.76M -0.13M -23.50M
Net income from continuing ops 2.05M 12.53M -34.40M 5.65M 77.85M
Net income applicable to common shares - - - 5.65M 77.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1974.72M 2120.96M 2226.88M 2210.76M 2142.50M
Intangible assets 224.30M 246.70M 277.83M 242.91M 277.62M
Other current assets 151.14M 88.76M 52.60M 77.36M 48.33M
Total liab 742.91M 877.65M 1037.92M 1080.62M 995.81M
Total stockholder equity 1231.81M 1243.31M 1188.95M 1130.14M 1146.69M
Deferred long term liab - - - 2.10M 51.70M
Other current liab 137.19M 145.45M 179.96M 235.35M 204.30M
Common stock 0.06M 0.06M 0.06M 0.06M 0.05M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.05M
Retained earnings 384.94M 382.89M 370.36M 390.73M 368.57M
Other liab - - - 46.20M 79.74M
Good will 737.95M 734.73M 735.81M 734.27M 738.90M
Other assets - - - 138.99M 225.59M
Cash 196.52M 369.20M 500.98M 330.36M 349.05M
Total current liabilities 476.61M 595.68M 367.79M 428.45M 876.16M
Current deferred revenue 283.48M 201.98M 132.28M 118.95M 112.20M
Net debt 7.83M 13.35M 113.11M 286.38M 179.01M
Short term debt 11.96M 185.03M 10.52M 10.76M 488.15M
Short long term debt - 174.32M - - 488.15M
Short long term debt total 204.34M 382.55M 614.09M 616.74M 528.06M
Other stockholder equity 855.67M 877.56M 831.97M 756.44M 786.47M
Property plant equipment - - - 93.96M 119.69M
Total current assets 680.07M 815.49M 927.57M 881.81M 780.70M
Long term investments 60.74M 52.74M 42.95M 32.92M 18.39M
Net tangible assets - - - 152.96M 130.17M
Short term investments 14.65M 12.47M 11.87M 11.49M 10.66M
Net receivables 216.86M 256.40M 263.89M 299.47M 240.89M
Long term debt 167.60M 166.40M 569.66M 566.57M -
Inventory 100.91M 88.66M 110.10M 147.55M 119.92M
Accounts payable 43.99M 51.78M 45.03M 63.39M 71.51M
Accumulated other comprehensive income -8.85M -17.20M -13.43M -17.09M -8.41M
Common stock total equity - - - 0.06M 0.05M
Retained earnings total equity - - - 390.73M 368.57M
Treasury stock - - - -290.32M -238.11M
Non currrent assets other 68.85M 75.53M 64.37M 164.50M 191.31M
Non current assets total 1294.65M 1305.47M 1299.31M 1328.95M 1361.79M
Capital lease obligations 36.75M 41.83M 44.43M 50.17M 39.91M
Long term debt total - - - 566.57M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -52.79M -59.90M -58.67M -412.50M
Change to liabilities - - - 10.64M 53.26M
Total cashflows from investing activities -60.36M -52.79M -55.02M -58.67M -412.50M
Net borrowings -175.00M -225.46M 0.00M - -
Total cash from financing activities -218.32M -235.58M 23.42M -20.95M 47.36M
Change to operating activities - - - 0.29M 10.06M
Net income 2.05M 12.53M -20.37M 5.65M 77.85M
Change in cash -147.58M -102.36M 148.14M -2.79M -134.30M
Begin period cash flow 398.61M 500.98M 352.83M 355.62M 489.92M
End period cash flow 251.03M 398.61M 500.98M 352.83M 355.62M
Total cash from operating activities 127.30M 187.72M 181.09M 77.78M 231.81M
Issuance of capital stock - - - - 0.00M
Depreciation 86.63M 89.75M 95.56M 99.17M 84.93M
Other cashflows from investing activities -9.78M -5.93M -13.54M -11.13M -383.53M
Dividends paid - - 4.40M - -
Change to inventory -11.22M 5.39M 38.02M -30.11M -25.70M
Change to account receivables 41.42M -5.00M 38.74M -60.36M -43.22M
Sale purchase of stock -77.60M 0.00M -7.37M -52.21M 67.35M
Other cashflows from financing activities 17.41M -48.70M 3.17M 31.26M 47.36M
Change to netincome - - - 31.61M 50.32M
Capital expenditures 40.41M 36.46M 41.47M 60.74M 58.34M
Change receivables - - - -75.71M -37.63M
Cash flows other operating - - - 44.61M 10.61M
Exchange rate changes - - - - -0.97M
Cash and cash equivalents changes - - - -1.84M -134.30M
Change in working capital -8.33M 58.33M 43.67M -73.47M -3.34M
Stock based compensation 44.50M 39.32M 55.30M 68.25M 53.16M
Other non cash items 3.74M 2.64M 17.98M 15.50M 22.48M
Free cash flow 86.89M 151.26M 139.62M 17.04M 173.47M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OMCL
Omnicell Inc		 -0.33
0.92%		 35.57 38.85 29.50 1.19 1.18 1.11 9.70
VEEV
Veeva Systems Inc Class A		 -0.78
0.26%		 304.77 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited		 -2.18
1.51%		 141.82 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock		 -1.11
1.38%		 79.43 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc		 -0.11
1.88%		 5.73 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

4220 North Freeway, Fort Worth, TX, United States, 76137

877 415 9990

https://www.omnicell.com

3485

Name Title Year Born
Mr. Randall A. Lipps Founder, Exec. Chairman, Pres & CEO 1957
Mr. Peter J. Kuipers Exec. VP & CFO 1972
Ms. Christine Mellon Exec. VP, Chief Admin. & People Officer 1963
Mr. Scott Peter Seidelmann Exec. VP & Chief Commercial Officer 1976
Mr. Joseph Brian Spears Sr. VP, Chief Accounting Officer & Corp. Controller 1960
Mr. Giri Chodavarapu Sr. VP & Chief Information Officer NA
Ms. Kathleen Nemeth Sr. VP of Investor Relations NA
Mr. Corey J. Manley Sr. VP & Chief Legal Officer NA
Ms. Roxanne Turner Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer NA
Mr. Jorge R. Taborga Exec. VP of Engineering & Integration Management Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…